Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.
Here are latest arrivals approved by the Food and Drug Administration.
More than 80% of clinical trial participants experienced complete or partial remission.
New drugsto treat multiple myeloma are producing better results for patients, with fewer side effects.
Here’s a list of the approved drugs to treat multiple myeloma. Click on any of the medications for more info on dosing, side effects...
The antibody-drug-conjugate produced an overall response rate of 31%.
Researchers identify a series of molecular abnormalities associated with greater risk of myeloma progression
O. David Dye, 77, a multiple myeloma survivor who lives in Troy, Alabama, is training to be a master gardener.
September was designated as National Blood Cancer Awareness Month in 2010 by United States Congress.
“The cancer care community urgently needs data on the effects of COVID-19, specifically in patients with cancer."
In 2009, March was declared Myeloma Awareness Month (MAM).
Researchers use single-cell RNA sequencing to map changes in immune microenvironment in myeloma precursor conditions.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.